Sequence: HIV-Tat (12-mer)
| Experiment Id | EXP002306 |
|---|---|
| Paper | Prolongation of Life in Rats with Malignant Glioma by Intranasal siRNA/Drug Codelivery to the Brain |
| Peptide | Tat-modified MPEG-PCL |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.1 mg/kg siRNA |
| Rna Concentration | 0.1 mg/kg |
| Mixing Ratio | N/P 30 |
| Formulation Format | polymeric micelle |
| Formulation Components | MPEG-PCL-Tat + CPT |
| Size Nm | 60.00 |
| Zeta Mv | 15.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Intracranial C6 glioma rat |
| Administration Route | intranasal |
| Output Type | survival benefit / tumor suppression |
| Output Value | Median survival ↑ to 28.4 days |
| Output Units | |
| Output Notes | Kaplan–Meier survival; HE tumor sections |
| Toxicity Notes | No systemic toxicity or mucosal damage |
| Curation Notes |